Abstract：【Objective】To investigate the clinical efficacy of sacubitril valsartan combined with pitavastatin in the treatment of coronary heart disease (CHD) with heart failure (HF).【Methods】A retrospective analysis was conducted on the clinical data of 82 patients with CHD combined with HF admitted to our hospital from February 2020 to February 2022. According to the treatment method, they were divided into the control group (treated with pitavastatin in addition to conventional treatment) and the observation group (treated with sacubitril in addition to the control group), with 41 patients in each group. Two groups were compared in terms of clinical efficacy, cardiac function indicators [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD)], 6-minute walk test (6MWT) distance, and quality of life [Minnesota Heart Failure Quality of Life Scale (LHFQ score)], and the incidence of adverse reactions during treatment was statistically analyzed. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, LVEF in both groups was higher than before treatment, while LVEDD and LVESD were lower than before treatment. The differences between the observation group and the control group were statistically significant (P<0.05). After treatment, the distance between the two groups of 6MWT distarce was greater than before treatment, and the LHFQ score was lower than before treatment. Moreover, the difference between the observation group and the control group was statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The combination of sacubitril valsartan and pitavastatin has a good therapeutic effect on CHD complicated with HF, significantly improving patients' cardiac function, enhancing their quality of life, and has high safety.
[1] KATTA N, LOETHEN T, LAVIE C J, et al. Obesity and coronary heart disease: epidemiology, pathology, and coronary artery imaging[J].Curr Probl Cardiol,2021,46(3):100655. [2] SALDARRIAGA C, ATAR D, STEBBINS A, et al. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction[J].Eur J Heart Fail,2022,24(5):782-790. [3] CHAN P, SHAO L, TOMLINSON B, et al. An evaluation of pitavastatin for the treatment of hypercholesterolemia[J].Expert Opin Pharmacother,2019,20(1):103-113. [4] ZHANG Y X, DU X X, WANG H X, et al. Sacubitril-valsartan cocrystal revisited: role of polymer excipients in the formulation[J].Expert Opin Drug Deliv,2021,18(4):515-526. [5] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694. [6] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789. [7] FUSARO M, TESSARIN G. Prevention of coronary artery disease-related heart failure: the role of computed tomography scan[J].Heart Fail Clin,2021,17(2):187-194. [8] 尹晓东,张刚,刘日辉,等.氯吡格雷联合曲美他嗪对冠心病合并心力衰竭患者的疗效[J].西北药学杂志,2021,36(3):463. [9] FICI F, FAIKOGLU G, TARIM B A, et al. Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention[J].High Blood Press Cardiovasc Prev,2022,29(2):137-144. [10] 吴丹娜,陈朝聪,徐文娟,等.沙库巴曲缬沙坦对高龄冠心病合并心力衰竭患者心室重塑的影响[J].西北药学杂志,2022,37(2):126-130. [11] LIU Z, WANG J, LI Y. Efficacy of sacubitril valsartan sodium tablet for the treatment of chronic heart failure: a systematic review protocol of randomized controlled trials[J].Medicine (Baltimore),2019,98(47):e18050. [12] ZHANG L, YAN K, ZHAO H, et al. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis[J].Ann Palliat Med,2022,11(3):1017-1027. [13] SUBRAMANIAN V B, KATARI N K, PONNAM V, et al. Stability-indicating reversed-phase-HPLC method development and validation for sacubitril/valsartan complex in the presence of impurities and degradation products: Robustness by quality-by-design approach[J].Biomed Chromatogr,2022,36(1):e5240. [14] 武云涛,王玉红,姚璐,等.沙库巴曲缬沙坦对高龄老年冠心病合并慢性心力衰竭患者心功能的影响[J].中国循证心血管医学杂志,2022,14(5):559-561.
2024, Vol. 41 
